Investigational Drug Information for Tavilermide

What is the development status for investigational drug Tavilermide?

Tavilermide is an investigational drug.

There have been 5 clinical trials for Tavilermide. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1^st 2013.

The most common disease conditions in clinical trials are Dry Eye Syndromes, Keratoconjunctivitis Sicca, and Keratoconjunctivitis. The leading clinical trial sponsors are Mimetogen Pharmaceuticals USA, Inc. and [disabled in preview].

Summary for Tavilermide

US Patents	0
International Patents	0
US Patent Applications	54
WIPO Patent Applications	12
Japanese Patent Applications	4
Clinical Trial Progress	Phase 3 (2013-10-01)
Vendors	31

Recent Clinical Trials for Tavilermide

Title	Sponsor	Phase
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye	Mimetogen Pharmaceuticals USA, Inc.	Phase 3
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye	Mimetogen Pharmaceuticals USA, Inc.	Phase 3
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease	Mimetogen Pharmaceuticals USA, Inc.	Phase 3

See all Tavilermide clinical trials

Clinical Trial Summary for Tavilermide

Top disease conditions for Tavilermide

Top clinical trial sponsors for Tavilermide

See all Tavilermide clinical trials

US Patents for Tavilermide

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Tavilermide Development Update and Market Projection

Last updated: September 3, 2026

Tavilermide, also known as MIM-D3, is an investigational topical ophthalmic treatment for dry eye disease. The small-molecule nerve growth factor mimetic was developed by Mimetogen Pharmaceuticals to stimulate corneal healing, tear production, and mucin secretion. Publicly available information does not show FDA approval, an active U.S. marketing application, an Orange Book listing, or a current commercial launch. Its development appears to have stalled after mid-stage clinical development, leaving its market value dependent on a potential restart, licensing transaction, or acquisition.

What is tavilermide and how does it work?

Tavilermide is a topical ophthalmic drug candidate designed to activate the TrkA receptor pathway associated with nerve growth factor. The intended effects include:

• Increased aqueous tear production
• Improved corneal epithelial recovery
• Increased mucin production
• Improvement in dry-eye symptoms
• Potential restoration of corneal nerve function

Tavilermide was developed for keratoconjunctivitis sicca, commonly called dry eye disease. Its mechanism differs from the immunomodulatory activity of cyclosporine and lifitegrast and from the secretagogue mechanisms of varenicline nasal spray and perfluorohexyloctane ophthalmic solution.

The proposed positioning was a disease-modifying or restorative topical therapy rather than a conventional lubricant.

What is the current development status of tavilermide?

Tavilermide is not an FDA-approved drug. Public records do not show a completed New Drug Application review, an FDA approval date, a commercial U.S. product, or an active Orange Book entry for tavilermide as of the latest publicly available information.

Development timeline

Period	Development event
2000s-early 2010s	Mimetogen Pharmaceuticals advances MIM-D3 as a topical treatment for dry eye disease
2010s	Early and mid-stage studies evaluate safety, tear production, corneal staining, and dry-eye symptoms
2015-2018	Phase 2 and Phase 2b development generates clinical data in patients with dry eye disease
After mid-stage development	Public evidence of a late-stage registration program or FDA submission becomes limited
Current public status	No FDA approval, Orange Book listing, marketed product, or confirmed commercial launch

The development program generated clinical interest because tavilermide attempted to address both symptoms and ocular-surface biology. The available public record does not establish that the candidate progressed into a successful pivotal Phase 3 program capable of supporting approval.

What clinical evidence supports tavilermide?

Clinical studies evaluated tavilermide in patients with dry eye disease using endpoints that included ocular discomfort, corneal staining, tear production, and other ocular-surface measures.

Reported development findings indicated that tavilermide had biological activity in some study settings. The principal commercial question was whether the treatment could produce consistent, statistically significant, and clinically meaningful results across the symptom and sign endpoints required for registration.

Dry-eye trials have a high placebo response and substantial variability among patients. A candidate can improve tear production or corneal staining without delivering a sufficiently large improvement in patient-reported symptoms. This has affected the development prospects of several dry-eye therapies.

The public record supports the following assessment:

Factor	Assessment
Mechanistic rationale	Strong
Early clinical activity	Present
Evidence of consistent late-stage efficacy	Not established publicly
FDA approval	None
Commercial availability	None
Current development momentum	Low or unclear

No public evidence establishes a completed regulatory filing based on the available development history.

When does tavilermide lose exclusivity?

There is no confirmed U.S. commercial exclusivity date because tavilermide has not received FDA approval.

Patent and regulatory exclusivity

Tavilermide may have been covered by patents relating to:

• The active compound
• TrkA agonist chemistry
• Ophthalmic formulations
• Use in dry eye disease
• Corneal wound healing
• Dosing and administration
• Combination treatment with other ocular therapies

The exact enforceable patent term depends on the issued claims, terminal disclaimers, patent-term adjustment, patent-term extension, maintenance status, and jurisdiction. A patent family filing date alone does not establish the final expiration date.

Because there is no FDA-approved reference listed drug, there is also no current Orange Book patent-certification framework for generic applicants. If tavilermide were revived and approved, generic competition would normally depend on the surviving formulation, composition, method-of-use, and manufacturing claims.

Generic entry risk

If tavilermide eventually reaches approval, generic entry would likely occur through an Abbreviated New Drug Application after relevant patents and regulatory exclusivity expire. The principal risks would include:

1. A relatively simple topical ophthalmic dosage form that may be technically reproducible.
2. Potentially limited chemical complexity compared with biologic ophthalmic products.
3. Formulation patents that may be easier to design around than composition-of-matter claims.
4. Generic substitution pressure if the product gains meaningful payer coverage.

The strongest protection would come from an unexpired composition-of-matter patent combined with approved method-of-use claims. Formulation-only protection would usually provide a narrower barrier.

What is the Orange Book status of tavilermide?

Tavilermide has no FDA Orange Book listing based on the public approval record. It has no approved reference listed drug designation, no listed FDA patent, and no public Paragraph IV litigation associated with an approved tavilermide product.

Paragraph IV challenges and litigation

No confirmed Paragraph IV challenge, Hatch-Waxman litigation, or settlement agreement involving an approved tavilermide product has been publicly identified in the available record.

This absence is primarily regulatory. Paragraph IV disputes generally arise after FDA approval or submission of an ANDA referencing an approved product. Since tavilermide has not reached that stage, generic litigation has not become a material issue.

Which companies are challenging or developing tavilermide?

No active generic challenger or competing developer has been publicly linked to tavilermide as a marketed or FDA-filed product.

Mimetogen Pharmaceuticals was the principal company associated with MIM-D3 development. The public record does not establish a current commercial partner with an active Phase 3 or registration program for tavilermide.

The relevant competitive companies in dry eye include:

Company	Product	Mechanism or category	Commercial status
AbbVie, through Allergan	Restasis, cyclosporine ophthalmic emulsion	Immunomodulator	Approved and marketed
Bausch + Lomb	Xiidra, lifitegrast ophthalmic solution	LFA-1 antagonist	Approved and marketed
Oyster Point, later part of Viatris operations	Tyrvaya, varenicline nasal spray	Nicotinic receptor agonist	Approved and marketed
Bausch + Lomb	Miebo, perfluorohexyloctane	Evaporative dry-eye therapy	Approved and marketed
Novartis	Xiidra in certain markets	LFA-1 antagonist	Commercialized through licensing arrangements
Novaliq, licensed to Bausch + Lomb	Miebo	Lipid-layer and evaporation treatment	Approved and marketed
Harrow	Vevye, cyclosporine ophthalmic solution	Immunomodulator	Approved and marketed

Tavilermide would enter a market with established branded therapies, generic cyclosporine competition, physician familiarity with multiple mechanisms, and increasing segmentation between aqueous-deficient and evaporative dry eye.

How does tavilermide compare with current dry-eye drugs?

Attribute	Tavilermide	Restasis	Xiidra	Tyrvaya	Miebo
Regulatory status	Investigational	Approved	Approved	Approved	Approved
Administration	Topical ophthalmic	Topical ophthalmic	Topical ophthalmic	Nasal spray	Topical ophthalmic
Primary concept	TrkA-mediated ocular-surface repair	Immunomodulation	Immunomodulation	Tear stimulation through nasal pathway	Evaporation reduction
Potential differentiation	Corneal healing, mucin, nerve pathway	Chronic inflammation control	Rapid symptom-focused anti-inflammatory approach	Non-ocular-surface administration	Evaporative dry eye
Generic competition	None currently	Present or emerging	Limited depending on market	None established	None established
Commercial risk	Clinical and regulatory execution	Mature market	High branded competition	Device and tolerability adoption	Differentiation and payer access

Tavilermide's commercial rationale would depend on demonstrating benefits beyond artificial tears and anti-inflammatory drugs. The strongest opportunity would be a patient segment with corneal epithelial damage, low tear production, neuropathic symptoms, or inadequate response to existing products.

How strong is the patent estate for tavilermide?

The patent estate cannot be treated as commercially strong solely because tavilermide has a novel mechanism. Its effective strength would depend on the status and breadth of issued claims.

Likely protection categories

A tavilermide patent estate could include:

• Composition-of-matter claims
• Pharmaceutical salts and stereoisomers
• Ophthalmic solutions and suspensions
• Preservative-free formulations
• Concentration and dosing claims
• Treatment of dry-eye disease
• Treatment of corneal epithelial defects
• Treatment of corneal nerve dysfunction
• Manufacturing and purification processes

Composition-of-matter claims generally provide the strongest protection. Method-of-use claims may provide meaningful protection if the FDA-approved label includes a narrow indication that generic applicants must avoid. Formulation patents can protect commercial products but may be vulnerable to design-around strategies.

No public record reviewed here establishes a current, enforceable patent expiration date for the complete tavilermide estate. The absence of an approved product also means that any future patent-term-extension analysis remains premature.

What manufacturing and intellectual-property barriers exist?

Tavilermide is a small molecule administered topically to the eye. Manufacturing barriers would likely be lower than those associated with biologic ophthalmic products, but commercial formulation still presents technical challenges.

Key barriers include:

• Maintaining chemical stability in an ophthalmic solution
• Achieving adequate ocular-surface exposure
• Preventing irritation and preservative-related toxicity
• Controlling impurities and degradation products
• Producing sterile batches at commercial scale
• Demonstrating container-closure compatibility
• Establishing reproducible delivery to the cornea

If the product requires a proprietary vehicle, preservative-free packaging, or a complex delivery system, formulation and device patents could add value. Those barriers would not necessarily prevent a generic competitor from developing a bioequivalent product.

Tavilermide is a small molecule, so biosimilar risk is not applicable. The relevant post-approval threat would be conventional generic competition, not biosimilar substitution.

What is the market projection for tavilermide?

The global dry-eye disease market is large, but market size alone does not support a high valuation for an inactive or pre-registration asset. The candidate would need renewed clinical development, a positive pivotal program, FDA approval, and commercial differentiation.

Market opportunity

A successful tavilermide launch could target:

• Patients inadequately controlled on cyclosporine or lifitegrast
• Patients with corneal staining and ocular-surface injury
• Patients with tear-deficient disease
• Patients who cannot tolerate chronic anti-inflammatory drops
• Patients with mixed dry eye and corneal nerve dysfunction

Scenario-based revenue projection

The following estimates are commercial scenarios, not reported company guidance.

Scenario	Key assumptions	Estimated U.S. peak sales
Low	Development restart, narrow label, limited payer coverage	$50 million-$150 million
Base	Successful Phase 3 program, differentiated efficacy, specialty launch	$200 million-$500 million
High	Clear superiority or strong adjunctive use, broad reimbursement	$600 million-$1.0 billion

A global peak-sales range of approximately $300 million to $1.5 billion would require successful commercialization outside the United States and a defensible clinical advantage. The upper end would be difficult to achieve without a differentiated label, durable intellectual-property protection, and evidence that tavilermide improves both symptoms and objective ocular-surface signs.

Revenue exposure for potential partners

For a licensee, tavilermide would represent a high-risk, milestone-driven asset rather than near-term revenue. Value would be concentrated in:

1. Rights to a differentiated dry-eye mechanism.
2. Access to a large specialty ophthalmology market.
3. Potential combination use with anti-inflammatory therapies.
4. The possibility of extending treatment into corneal healing or nerve-related ocular disease.

A partner would likely demand updated clinical data, freedom-to-operate analysis, patent-status confirmation, and a regulatory development plan before assigning material deal value.

What generic launch scenarios exist for tavilermide?

Three launch scenarios are relevant:

Scenario 1: No further development

Tavilermide remains an inactive clinical asset with no commercial revenue. Its value is limited to intellectual property, data, and potential licensing.

Scenario 2: Strategic restart

A pharmaceutical company acquires or licenses the program, conducts additional Phase 2 or Phase 2b work, and selects a narrower target population. This scenario could preserve the asset but would delay launch by several years.

Scenario 3: Full registration program

The sponsor conducts pivotal trials, submits an NDA, secures FDA approval, and launches tavilermide as a differentiated dry-eye therapy. A realistic development-to-launch period would likely be several years, depending on the clinical package and regulatory requirements.

Generic entry would generally occur only after approval, patent expiry, or an authorized launch under a settlement or license agreement. No such agreement has been publicly confirmed for tavilermide.

Key Takeaways

• Tavilermide, or MIM-D3, is an investigational topical TrkA agonist for dry eye disease.
• Mimetogen Pharmaceuticals was the principal developer associated with the program.
• The candidate has no FDA approval, Orange Book listing, confirmed NDA approval, or commercial launch.
• Public development evidence supports early and mid-stage clinical activity but does not establish a successful late-stage registration program.
• No confirmed Paragraph IV challenge, generic litigation, or settlement agreement is associated with an approved tavilermide product.
• Tavilermide's potential differentiation is ocular-surface repair, tear stimulation, mucin production, and possible corneal nerve benefits.
• A restarted program could support estimated U.S. peak sales of roughly $200 million-$500 million in a base case.
• The principal risks are clinical reproducibility, regulatory reactivation, patent-term verification, payer access, and competition from Restasis, Xiidra, Tyrvaya, Miebo, and other dry-eye products.
• Biosimilar competition is irrelevant because tavilermide is a small molecule. Generic competition would become relevant only after approval.

FAQs About Tavilermide

Is tavilermide FDA approved?

No. Tavilermide does not have an FDA approval or a marketed U.S. product.

What company developed MIM-D3?

Mimetogen Pharmaceuticals was the company primarily associated with the development of MIM-D3, later known as tavilermide.

Is tavilermide a biologic or a small molecule?

Tavilermide is a small-molecule ophthalmic drug candidate. It is not a biologic and would not face biosimilar competition.

Could tavilermide be used with Restasis or Xiidra?

Combination use is commercially plausible because the mechanisms differ, but no approved combination indication has been established for tavilermide.

What is the investment outlook for tavilermide?

The asset has option value because dry eye is a large market and tavilermide has a differentiated mechanism. Its investment profile remains high risk because no approval, active commercial program, or verified late-stage development pathway is publicly established.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. ClinicalTrials.gov. (n.d.). Search results for tavilermide and MIM-D3 clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/

4. Mimetogen Pharmaceuticals, Inc. (n.d.). Tavilermide ophthalmic development information. Company materials.

5. U.S. Food and Drug Administration. (2023). FDA approves new treatment for dry eye disease. https://www.fda.gov/

6. U.S. Food and Drug Administration. (2023). FDA approves Miebo for dry eye disease. https://www.fda.gov/